MX355177B - Composicion farmaceutica de avidina oxidada adecuada para inhalacion. - Google Patents
Composicion farmaceutica de avidina oxidada adecuada para inhalacion.Info
- Publication number
- MX355177B MX355177B MX2014001176A MX2014001176A MX355177B MX 355177 B MX355177 B MX 355177B MX 2014001176 A MX2014001176 A MX 2014001176A MX 2014001176 A MX2014001176 A MX 2014001176A MX 355177 B MX355177 B MX 355177B
- Authority
- MX
- Mexico
- Prior art keywords
- inhalation
- oxidised
- pharmaceutical composition
- avidin
- avidin suitable
- Prior art date
Links
- 108090001008 Avidin Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11006338 | 2011-08-02 | ||
| PCT/EP2012/064576 WO2013017494A1 (en) | 2011-08-02 | 2012-07-25 | Pharmaceutical composition of oxidised avidin suitable for inhalation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014001176A MX2014001176A (es) | 2014-07-14 |
| MX355177B true MX355177B (es) | 2018-04-09 |
Family
ID=46581966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014001176A MX355177B (es) | 2011-08-02 | 2012-07-25 | Composicion farmaceutica de avidina oxidada adecuada para inhalacion. |
Country Status (19)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2941243A4 (en) | 2013-01-04 | 2016-09-14 | Massachusetts Inst Technology | SURFACE BINDING IN THE ADMINISTRATION OF A MEDICAMENT ON NANOPARTICLE BASE IN A TISSUE |
| EP3458097A4 (en) * | 2016-05-19 | 2020-01-08 | University of Miami | TARGETED DELIVERY OF THERAPEUTIC AGENTS AND IMAGING REAGENTS TO CANCER PANCREAS CELLS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5384128A (en) * | 1993-03-02 | 1995-01-24 | University Of Alabama Research Foundation | Method of and compounds for treatment for cystic fibrosis |
| WO1995003034A1 (en) | 1993-07-19 | 1995-02-02 | Amgen Inc. | Stabilization of aerosolized proteins |
| DE69830305T2 (de) * | 1997-02-20 | 2006-02-02 | Dime, David S., Toronto | Ortsspezifische arzneimittel verabreichung |
| EP1169053A1 (en) * | 1999-04-13 | 2002-01-09 | Inhale Therapeutic Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| ITRM20010079A1 (it) | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
| ITRM20030196A1 (it) * | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
| BRPI0517204A (pt) * | 2004-12-17 | 2008-09-30 | Cipla Ltd | sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol |
| GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| US8562947B2 (en) * | 2007-08-02 | 2013-10-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Oxidized avidin with high residency time in the treated tissues |
| EP2106806A1 (en) | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticles for targeted delivery of active agents to the lung |
| TW201031436A (en) * | 2009-02-16 | 2010-09-01 | Univ Nat Taiwan | Pharmaceutical composition for inhalation delivery and fabrication method thereof |
-
2012
- 2012-07-25 EA EA201490401A patent/EA026453B1/ru not_active IP Right Cessation
- 2012-07-25 PH PH1/2014/500193A patent/PH12014500193A1/en unknown
- 2012-07-25 KR KR1020147001707A patent/KR101966630B1/ko active Active
- 2012-07-25 JP JP2014523289A patent/JP6019118B2/ja active Active
- 2012-07-25 DK DK12740137.0T patent/DK2739314T3/da active
- 2012-07-25 ES ES12740137T patent/ES2729549T3/es active Active
- 2012-07-25 CN CN201280037217.9A patent/CN103717239B/zh active Active
- 2012-07-25 MX MX2014001176A patent/MX355177B/es active IP Right Grant
- 2012-07-25 BR BR112014002593-2A patent/BR112014002593B1/pt not_active IP Right Cessation
- 2012-07-25 CA CA2842276A patent/CA2842276C/en active Active
- 2012-07-25 EP EP12740137.0A patent/EP2739314B1/en active Active
- 2012-07-25 PL PL12740137T patent/PL2739314T3/pl unknown
- 2012-07-25 WO PCT/EP2012/064576 patent/WO2013017494A1/en not_active Ceased
- 2012-07-25 PT PT12740137T patent/PT2739314T/pt unknown
- 2012-07-25 UA UAA201402021A patent/UA114482C2/uk unknown
- 2012-07-25 AU AU2012292229A patent/AU2012292229B2/en active Active
- 2012-07-25 US US14/236,445 patent/US9872831B2/en active Active
-
2014
- 2014-01-22 IL IL230597A patent/IL230597A0/en active IP Right Grant
- 2014-02-27 ZA ZA2014/01921A patent/ZA201401921B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012292229A1 (en) | 2014-02-13 |
| EP2739314B1 (en) | 2019-05-22 |
| WO2013017494A1 (en) | 2013-02-07 |
| PL2739314T3 (pl) | 2019-09-30 |
| UA114482C2 (uk) | 2017-06-26 |
| CA2842276A1 (en) | 2013-02-07 |
| CA2842276C (en) | 2020-11-24 |
| KR20140047668A (ko) | 2014-04-22 |
| MX2014001176A (es) | 2014-07-14 |
| US9872831B2 (en) | 2018-01-23 |
| EA201490401A1 (ru) | 2014-05-30 |
| AU2012292229B2 (en) | 2017-08-03 |
| JP6019118B2 (ja) | 2016-11-02 |
| DK2739314T3 (da) | 2019-06-24 |
| IL230597A0 (en) | 2014-03-31 |
| JP2014521675A (ja) | 2014-08-28 |
| PT2739314T (pt) | 2019-06-21 |
| BR112014002593A2 (pt) | 2017-03-01 |
| KR101966630B1 (ko) | 2019-04-09 |
| ES2729549T3 (es) | 2019-11-04 |
| ZA201401921B (en) | 2015-05-27 |
| BR112014002593B1 (pt) | 2022-11-29 |
| CN103717239B (zh) | 2017-08-01 |
| US20140134106A1 (en) | 2014-05-15 |
| CN103717239A (zh) | 2014-04-09 |
| EA026453B1 (ru) | 2017-04-28 |
| PH12014500193A1 (en) | 2014-03-24 |
| NZ620202A (en) | 2016-05-27 |
| EP2739314A1 (en) | 2014-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX349004B (es) | Nuevos compuestos. | |
| IN2014MN00986A (cg-RX-API-DMAC7.html) | ||
| EA201400591A1 (ru) | Ингалятор | |
| CY1117372T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους | |
| GB201118656D0 (en) | New compounds | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| GB201209613D0 (en) | New compounds | |
| EA201400392A1 (ru) | ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb | |
| IN2014DN00288A (cg-RX-API-DMAC7.html) | ||
| IN2014MN00093A (cg-RX-API-DMAC7.html) | ||
| AU2012205878A8 (en) | miRNA for treating diseases and conditions associated with neo-angiogenesis | |
| IN2014MN01378A (cg-RX-API-DMAC7.html) | ||
| PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| TN2014000185A1 (en) | Polyethylene glycol based prodrug of adrenomedullin and use thereof | |
| BR112013022052A2 (pt) | ligantes antagonísticos de dr3 | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| WO2012125408A8 (en) | Pegylated apelin and uses thereof | |
| MX370253B (es) | Composiciones de compuestos de jasmonato y métodos de uso de las mismas. | |
| EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
| MX340536B (es) | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). | |
| MX355177B (es) | Composicion farmaceutica de avidina oxidada adecuada para inhalacion. | |
| HK1202868A1 (en) | Carboxamide-substituted heteroaryl-pyrazoles and the use thereof | |
| LV14848A (lv) | Farmaceitiska kompozīcija trimetilamīna N-oksīda līmeņa pazemināšanai | |
| WO2012123561A3 (de) | Agens zur prophylaxe und behandlung altersassoziierter krankheiten und störungen sowie zur verlängerung der lebensdauer | |
| GB201206984D0 (en) | New therapeutic use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: ALFASIGMA S.P.A. |
|
| FG | Grant or registration |